Today, on the 26 March 2001 the 1st participant in the first SATVI BCG- randomised clinical trial was enrolled. Adele Baleta writes in the Daily Maverick about the work that the South African Tuberculosis Vaccine Initiative has been doing the past 20 years in fighting TB.
On Friday 26 March 2021, SATVI will celebrate its 20th birthday to mark the enrolment in 2001 of the first participant in the first SATVI TB vaccine trial a randomised controlled trial of intradermal vs percutaneous BCG vaccination, Hawkridge BMJ 2008.
Cape Town: Researchers at the South African Tuberculosis Vaccine Initiative (SATVI) research site in Worcester have started recruitment for a phase II vaccine trial to see if the M72/AS01E TB vaccine is safe and immunogenic in people living with HIV.
Associate Professor Elisa Nemes, Dr Michele Tameris, Dr Virginie Rozot, Professor Thomas Scriba, and Dr Benjamin Kagina have written an opinion piece in which they explain the process vaccines and drugs have to go through before they can be approved for human use. This article appeared in the Health 24.